MHRA paediatric investigation plan
tixagevimab (AZD8895) (tixagevimab (AZD8895))
MHRA paediatric investigation plan MHRA-100028-PIP01-21 · Agreement
Key facts
| PIP number | MHRA-100028-PIP01-21 |
|---|---|
| Active substances | tixagevimab (AZD8895), cilgavimab (AZD1061) |
| Therapeutic areas | Infectious diseases |
| Conditions | Prevention of Coronavirus Disease 2019 (COVID-19), Treatment of Coronavirus Disease 2019 (COVID-19) |
| Decision | P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) |
| Published | Nov 3, 2021 |
| MHRA record | cms.mhra.gov.uk |
About MHRA paediatric investigation plans
A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.
Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date: